Even if bisantrene doesn’t provide cardioprotection in human, it is still a very valuable asset from an anticancer perspective. Just the opportunity in AML alone is enough to justify the current MC of RAC.
All small biotechs come with risk, you don’t need me to tell you what they are.
- Forums
- ASX - By Stock
- Cardioprotection thread
Even if bisantrene doesn’t provide cardioprotection in human, it...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M |
Open | High | Low | Value | Volume |
$1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1996 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 1305 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4387 | 1.600 |
1 | 31000 | 1.590 |
1 | 10000 | 1.585 |
2 | 8233 | 1.560 |
4 | 15571 | 1.550 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 585 | 1 |
1.700 | 17181 | 1 |
1.750 | 30400 | 2 |
1.755 | 990 | 1 |
1.820 | 1000 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |